AI-driven precision medicine company Exscientia (Nasdaq: EXAI) has announced a headcount reduction of between 20% and 25%.
The jobs will go at the UK firm this year, impacting some areas of target identification, precision medicine, experimentation, engineering and infrastructure.
The redundancies are part of a series of efficiency measures through the rest of the year that are designed to streamline the company’s operations, which it expects to result in annual savings of $40 million or more beginning in 2025.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze